JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
About
07 May 2023
Last Updated: 24 February 2026
Hits: 1144
  • Type 2 Diabetes
  • Metabolic Health
  • Obesity Care
  • JCS/T2D
  • Health Communication

About

JCS/T2D focuses on bringing clarity to type 2 diabetes and obesity care. We combine lived experience, research literacy, and analytical insight to make complex topics easier to understand and discuss.

Who We Are

We are advocates committed to thoughtful, evidence-informed communication.
We learn. We share. We inform.
We change the conversation.

Our perspective draws from lived experience, continuing education, and the disciplined analytical approach of JCS Analytics. This combination helps us connect research, everyday reality, and public understanding in a way that corrects misconceptions and highlights what’s possible.

What We Do

We explore the intersection of data, health, and real-world decision-making. We look for patterns that matter and explain them in ways that support clearer thinking.

Our work includes:

  • Translating research and real-world evidence into accessible insight
  • Clarifying topics such as GLP-1 therapy, obesity as a chronic disease, and CGM data
  • Bridging the gap between scientific information and how people experience these conditions

Why It Matters

Type 2 diabetes and obesity are often framed around blame or restriction. That framing doesn’t help people move forward.

We shift the focus toward:

  • Progress instead of blame
  • Understanding instead of stigma
  • Practical strategies that support better outcomes

Our goal is to make it easier for individuals, families, and the broader community to talk about these conditions with confidence and compassion.

How We Approach the Work

We communicate with clarity, empathy, and intent.

We explain what the evidence shows, acknowledge what remains uncertain, and avoid overstating what data can or cannot say.

Above all, we aim to make information easier to understand and easier to use.

Paying attention to patterns isn’t just analytical. It’s practical.
In health, early signals often appear long before outcomes change. Recognizing them early gives people more options and better chances to act.

Our Ethos

Sound judgment begins where certainty ends.

Why Novo Nordisk Appears Frequently

Novo Nordisk provides more publicly accessible educational materials, media assets, and research updates than many other companies. Their open communication culture and partnerships with universities and public institutions create more opportunities for responsible analysis.

Articles

  • Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
  • A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
  • Wegovy Will Not Go OTC: What the Sources Actually Say
  • Bridging Data and Healthcare in the Nordics
  • How Well Do My CGM and BGM Readings Match?
  • Epigenetic Clues to Heart Risk in Type 2 Diabetes
  • Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
  • Why mRNAs Are a Good Option for Vaccines
  • Why I Took Medical Courses to Strengthen My Data Skills
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • What the 2025 Diabetes Care Updates Mean for You
  • How an Hour-by-Hour View Transforms Time in Range Insights
  • Successfully Completed: Diabetes – A Global Challenge
  • Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
  • Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
  • FDA Issues Alert on Compounded Semaglutide Dosing Errors
  • Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
  • Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea

News

April 2026

  • New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
  • Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
  • Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care

March 2026

  • Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
  • Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
  • FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
  • FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
  • Zealand Pharma Reports Phase 2 Results for Petrelintide

February 2026

  • REDEFINE-4 Results: What They Mean for Patients
  • Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Semaglutide
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • FDA Approval
  • Diabetes
  • Obesity
  • Diabetes Management
  • Continuous Glucose Monitoring
  • Orforglipron
  • Mounjaro
  • Clinical Trials
  • Metabolic Health
  • Obesity Care
  • Dexcom
  • CGM
  • FDA
  • Weight Loss
  • Oral Semaglutide
  • Rybelsus
  • Diabetes Treatment
  • Once-Weekly Insulin
  • Dexcom G7
  • Liraglutide

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • About
  • About
 
Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.